Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01586169
Other study ID # CNAM/AZIVAL/01
Secondary ID 0958/FMPOS
Status Completed
Phase N/A
First received April 23, 2012
Last updated April 24, 2012
Start date February 2010
Est. completion date February 2010

Study information

Verified date April 2012
Source Centre d'Appui à la lutte contre la Maladie
Contact n/a
Is FDA regulated No
Health authority Mali: comités d'éthique
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the triple co administration of albendazole, ivermectin and azithromycine is as safe as the current treatment scheme that consists to treat with albendazole plus ivermectin together and a week later to treat with azithromycin in areas co endemic for lymphatic filariasis and trachoma.


Description:

Infectious diseases such as trachoma and lymphatic filariasis are public health problems in regions of Africa and Asia. Elimination programs exist for the two diseases, and their treatment by different groups of health workers is both costly and inefficient.

Thus, a study evaluating the safety and feasibility of an integrated mass treatment of trachoma and lymphatic filariasis with azithromycin associated with albendazole and ivermectin was instituted in 4 villages of the region of Sikasso in Mali (West Africa) co endemic for lymphatic filariasis and trachoma.

It was an open label randomized clusters type on the assessment of the safety of the triple co administration of azithromycin, ivermectin and albendazole (experimental regimen) as compared to the administration of the co administration of albendazole plus ivermectin followed by the that of azithromycin a week later (current standard recommended regimen) within subjects of 5 to 65 years old, willing and able to swallow the study drugs.

Clinical evaluation of adverse events in all study participants was done on day 0, day 8, and day 15 after the treatment.


Recruitment information / eligibility

Status Completed
Enrollment 3000
Est. completion date February 2010
Est. primary completion date February 2010
Accepts healthy volunteers No
Gender Both
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria:

- Must have been residing in the village for at least three months;

- Must be 90 cm tall or more;

- Must be between 5 years and 65 years of age;

- Must not be pregnant;

- Must not be lactating.

Exclusion Criteria:

- Subjects under 5 years of age or less than 90 cm in height;

- Subjects over 65 years of age;

- Subjects who cannot swallow tablets;

- Subjects who are sick and bedridden;

- Pregnant women (clinical appreciation in the study);

- Lactating women;

- History of allergies to the drugs being studied (azithromycin, ivermectin, albendazole).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once

Locations

Country Name City State
Mali Centre National D'Appui a la lutte contre la Maladie Bamako

Sponsors (2)

Lead Sponsor Collaborator
Centre d'Appui à la lutte contre la Maladie International Trachoma Initiative

Country where clinical trial is conducted

Mali, 

Outcome

Type Measure Description Time frame Safety issue
Primary Establish the incidence of adverse events associated with the mass triple drug administration From Day 0 to Day 15 post treatment Yes
Secondary Establish the incidence of serious adverse events associated with the mass triple drug administration From Day 0 to Day 15 post treatment Yes
See also
  Status Clinical Trial Phase
Completed NCT01050517 - Safety and Efficacy of Drug Combinations Against Triple Infections N/A
Completed NCT01050374 - Safety and Efficacy of Drug Combinations Against Schistosomiasis N/A
Completed NCT01050452 - Safety and Efficacy of Drug Combinations Against Trichuris Trichiura N/A
Recruiting NCT00344188 - Diagnosis and Treatment of Leishmania Infections
Active, not recruiting NCT02653898 - Malaria Elimination Pilot Study in Military Forces in Cambodia Phase 4
Completed NCT01425073 - Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya N/A
Completed NCT01533961 - Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Phase 1
Completed NCT05979207 - Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum Phase 1